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ABSTRACT 
Human Immunodeficiency Virus (HIV) is a T-lymphotrophic retrovirus that is 
the causative agent of Acquired Immunodeficiency Syndrome and is estimated to 
currently infect approximately 40 million people worldwide. Life-extending therapies 
are credited for the precipitous drop in HIV-related mortality in developed countries, 
but their high costs prevent widespread distribution in developing countries. To date, 
all attempts to produce a vaccine capable of preventing or controlling an HIV infection 
have failed, but a comprehensive explanation for these failures has yet to emerge from 
the available data. In this thesis the first chapter provides an overview of the 
pandemic, the antigenic properties of gp120 and gp41, which are the two 
glycoproteins that comprise the outer envelope spike of the virus, and the broadly 
neutralizing antibodies that have been isolated against them. The second and third 
chapters discuss biophysical characterizations of these monoclonal antibodies and 
newly designed molecules derived from them. Based on a comparison of these data 
with pre-existing research, a novel hypothesis called the “island effect” was developed 
and is presented as a possible explanation for the consistent failure of the human 
immune system to respond to infection or vaccination with an effective humoral 
response. The final chapter summarizes ongoing investigations in the capacities of 
broadly neutralizing monoclonal antibodies to recruit antibody-dependent cellular 
cytotoxicity, a mechanism by which antibodies can trigger the lysis of HIV-infected 
cells by the innate immune system. 
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